United Therapeutics' inhaled PAH treatment approved in US
This article was originally published in Scrip
Executive Summary
The US FDA has approved United Therapeutics' inhaled formulation of treprostinil, Tyvaso, for the treatment of pulmonary arterial hypertension (PAH).